过去一年中添加的文章，按日期排序
Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK
P Huang, F Ji, AHK Cheung, K Fu, Q Zhou, X Ding… - Cell Host & Microbe, 2024 - cell.com
10 天前 - … spontaneous CRC models of KRAS-wild-type CRC. P. stomatis also abrogates
BRAF … to multiple RTK blockers through alternative ERBB2 activation. RTK inhibitors are key …
BRAF … to multiple RTK blockers through alternative ERBB2 activation. RTK inhibitors are key …
Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer
H Miyashita, DS Hong - Journal of Cancer Immunology, 2024 - scientificarchives.com
12 天前 - … of the high prevalence of KRAS mutation across many types of cancer [5], KRAS …
Data of KRAS G12C inhibitor combined with RTK inhibitor for KRAS G12C mutated advanced …
Data of KRAS G12C inhibitor combined with RTK inhibitor for KRAS G12C mutated advanced …
Aberrant Expression of Sprouty2 In Human Colon Cancer
AS BAESMAT, B BAYRAKDAR - Clinical Medicine And Health Research …, 2024 - cmhrj.com
39 天前 - … that SPRY2 inhibits the RAS/MAPK/ERK pathway and promotes cancer invasion in
KRAS-… , cell proliferation, or invasion in KRAS-mutant CRCs. High SPRY2 expression was …
KRAS-… , cell proliferation, or invasion in KRAS-mutant CRCs. High SPRY2 expression was …
Genomic and biomarker analysis of immunotherapy combined with chemotherapy treated for patients with metastatic BTC cancer: A real world study.
M Gou, G Dai, ZK Wang - 2024 - ascopubs.org
67 天前 - … a survival benefit with the immune checkpoint inhibitor (ICI) plus chemotherapy (GemCis…
Results: 47 patients received immune checkpoint inhibitor (ICI) plus with chemotherapy …
Results: 47 patients received immune checkpoint inhibitor (ICI) plus with chemotherapy …
MEK inhibitor combined with RTK inhibitor (trametinib plus anlotinib) in non-G12C KRAS-mutant non-small cell lung cancer: A new strategy.
B Han, J Lu, H Zhong, T Chu, W Zhang, M Hu, C Shi… - 2024 - ascopubs.org
67 天前 - … inhibition of MEK/RTKs pathways via trametinib and anlotinib showed preliminary
activity in non-G12C KRAS-mutant … for those non-G12C KRAS-mutant lung cancer patients via …
activity in non-G12C KRAS-mutant … for those non-G12C KRAS-mutant lung cancer patients via …
Characterization of BTX-10908, a first-in-class, orally bioavailable SOS1 bifunctional degrader for the treatment of KRAS-and RTK-driven cancers.
K Begovich, A Schoolmeesters, E Martinez-Terroba… - 2024 - ascopubs.org
67 天前 - … these inhibitors resulting in synergistic effects in in vitro proliferation assays and
enhanced tumor growth inhibition in KRAS-mutant … therapies of KRAS and RTK-driven cancers. …
enhanced tumor growth inhibition in KRAS-mutant … therapies of KRAS and RTK-driven cancers. …
KRAS G12C inhibitors in the treatment of metastatic colorectal cancer
A Xiao, M Fakih - Clinical Colorectal Cancer, 2024 - Elsevier
82 天前 - … KRAS mutations contribute substantially to the overall colorectal cancer burden
and … of KRAS G12C mutated CRC, new challenges are on the horizon. Alternative RTK …
and … of KRAS G12C mutated CRC, new challenges are on the horizon. Alternative RTK …
Activity and resistance to KRASG12C inhibitors in non-small cell lung cancer and colorectal cancer
W Ye, X Lu, Y Qiao, WB Ou - Biochimica et Biophysica Acta (BBA)-Reviews …, 2024 - Elsevier
88 天前 - … KRAS mutations. Due to the presence of alternative resistance pathways, the use
of KRAS G12C inhibitors as a … to KRAS inhibitors: 1) RTK activation due to EGFR mutation or …
of KRAS G12C inhibitors as a … to KRAS inhibitors: 1) RTK activation due to EGFR mutation or …
[PDF][PDF] Discovery of BTX-10908, a first-in-class, orally bioavailable SOS1 bifunctional degrader, for the treatment of RTK-and KRAS-driven tumors
K Begovich, A Schoolmeesters, EMTN Rajapakse… - biotheryx.com
90 天前 - … inhibition of downstream signaling & cell proliferation, both of which is more
potent than SOS1 inhibition… ability to synergize with various inhibitors targeting the RTK-RAS-MAPK …
potent than SOS1 inhibition… ability to synergize with various inhibitors targeting the RTK-RAS-MAPK …
RAF and MEK Inhibitors in Non-Small Cell Lung Cancer
C Adamopoulos, KA Papavassiliou… - International Journal of …, 2024 - mdpi.com
102 天前 - … non-V600-, KRAS-, or RTK-mutant NSCLC. The next generation of RAF and MEK
inhibitors, with … class III BRAF mutations, certain KRAS mutations, such as KRASG12C, EGFR …
inhibitors, with … class III BRAF mutations, certain KRAS mutations, such as KRASG12C, EGFR …